Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01529502 · ClinicalTrials.gov registry record · Phase 2

Pilot Study About the Harmful Effects of Blood Storage on Overweight People and the Role of iNO in This Setting

A Phase 2 study, sponsored by Massachusetts General Hospital.

Completed
Registry status
Phase 2
Development phase
14
Enrollment target

NCT01529502: Completed Phase 2 study, sponsored by Massachusetts General Hospital.

NCT01529502 is a Phase 2 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 14 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (89% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT01529502, a Phase 2 study, has completed, sponsored by Massachusetts General Hospital.

COMPLETED
Registry status
Phase 2
Development phase
14 participants
Enrollment target

Study Summary

The purpose of this study is to determine whether storage time affects how human body responds to autologous blood transfusion. An autologous blood transfusion is when a person donates blood and then receives that same blood back in the transfusion. We also want to find out if in this situation inhaled nitric oxide can help to prevent the potential reduction of vasodilation capacity. Vasodilation capacity is the ability of the blood vessel to widen when needed.

Primary Outcome

Pulmonary vasoconstriction was measured by estimation of Systolic Pulmonary Artery Pressure in millimeter of mercury (mmHg) by trans-thoracic echocardiography

Interventions

  • PROCEDURE Red blood Cells auto-transfusion
  • DRUG Inhaled Nitric Oxide (iNO) administration

Trial Details

FieldValue
Enrollment Target 14 participants
Start Date 2012-03
Est. Completion 2013-12
Phase Phase 2
Massachusetts General Hospital

2,032 total trials

What the finished NCT01529502 record still lists

NCT01529502 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (89% lower).

The record links to 0 conditions, and to 2 interventions - of which Red blood Cells auto-transfusion is the first listed.

NCT01529502 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01529502 about?

NCT01529502 is a clinical study titled "Pilot Study About the Harmful Effects of Blood Storage on Overweight People and the Role of iNO in This Setting". The purpose of this study is to determine whether storage time affects how human body responds to autologous blood transfusion. An autologous blood transfusion is when a person donates blood and then receives that same blood back in the transfusion. We also want to find out if in this situation inha...

What is the current status of trial NCT01529502?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 14 participants. The study started on 2012-03. Estimated completion is 2013-12.

What interventions are being tested in trial NCT01529502?

The interventions under investigation include: Red blood Cells auto-transfusion (PROCEDURE), Inhaled Nitric Oxide (iNO) administration (DRUG).

Who is sponsoring clinical trial NCT01529502?

This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01529502's enrollment target sits among peer trials

14 1941st of 2000 higher than 54 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02523092 · 14 participants · Phase 4

    Use of CXCL9 as a Biomarker of Acthar Efficacy

  • NCT04263285 · 14 participants · NA

    Treatment of Depression Post-SCI

  • NCT04743271 · 14 participants · NA

    Food and Circadian Timing

  • NCT05065671 · 14 participants · Phase 1

    Microbiome Derived Metabolism and Pharmacokinetics

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01529502, the US trial registry maintained by the National Library of Medicine. NCT01529502 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.